{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:54:41Z","timestamp":1787817281197,"version":"build-2784847793"},"reference-count":105,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.beha.2025.101641","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T12:11:47Z","timestamp":1752581507000},"page":"101641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Precursor plasma cell disorders: Classification, risk stratification, and emerging role of early interception"],"prefix":"10.1016","volume":"38","author":[{"given":"Tarek H.","family":"Mouhieddine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-4277","authenticated-orcid":false,"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2025.101641_bib1","author":"Surveillance"},{"issue":"13","key":"10.1016\/j.beha.2025.101641_bib2","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.beha.2025.101641_bib3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-019-0263-z","article-title":"Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement","volume":"9","author":"Murray","year":"2019","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.beha.2025.101641_bib4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Thorsteinsdottir","year":"2023","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.beha.2025.101641_bib5","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.beha.2025.101641_bib6","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4065\/mcp.2010.0520","article-title":"Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence","volume":"85","author":"Rajkumar","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.beha.2025.101641_bib7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2025.101641_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3816\/CLML.2011.n.011","article-title":"IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenstrom's macroglobulinemia (SWM)","volume":"11","author":"Kyle","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"25","key":"10.1016\/j.beha.2025.101641_bib9","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2025.101641_bib10","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","article-title":"Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden","volume":"123","author":"Turesson","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2025.101641_bib11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network","volume":"99","author":"van de Donk","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.beha.2025.101641_bib12","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2025.101641_bib13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7326\/M23-2540","article-title":"Development of a multivariable model to predict the need for bone marrow sampling in persons with monoclonal gammopathy of undetermined significance : a cohort study nested in a clinical trial","volume":"177","author":"Eythorsson","year":"2024","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.beha.2025.101641_bib14","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.beha.2025.101641_bib15","article-title":"Prospective evaluation of whole-body MRI versus FDG PET\/CT for lesion detection in participants with myeloma","volume":"3","author":"Messiou","year":"2021","journal-title":"Radiol Imag Cancer"},{"issue":"9727","key":"10.1016\/j.beha.2025.101641_bib16","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.beha.2025.101641_bib17","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101641_bib18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjh.18232","article-title":"Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage","volume":"199","author":"Wennmann","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2025.101641_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.61","article-title":"Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma","volume":"8","author":"Mellgard","year":"2024","journal-title":"Hemasphere"},{"issue":"33","key":"10.1016\/j.beha.2025.101641_bib20","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2025.101641_bib21","first-page":"1874","article-title":"t(11;14) status is stable between diagnosis and relapse and concordant between detection methodologies based on fluorescence in situ hybridization and next-generation sequencing in patients with multiple myeloma","volume":"109","author":"Avet-Loiseau","year":"2024","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.beha.2025.101641_bib22","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1158\/1078-0432.CCR-21-3695","article-title":"Myeloma genome project panel is a comprehensive targeted genomics panel for molecular profiling of patients with multiple myeloma","volume":"28","author":"Sudha","year":"2022","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"12","key":"10.1016\/j.beha.2025.101641_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-019-0264-y","article-title":"Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma","volume":"9","author":"Yellapantula","year":"2019","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.beha.2025.101641_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.beha.2025.101641_bib25","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jmoldx.2020.04.002","article-title":"Mass spectrometry-based method targeting Ig variable regions for assessment of minimal residual disease in multiple myeloma","volume":"22","author":"Martins","year":"2020","journal-title":"J Mol Diagn"},{"issue":"1","key":"10.1016\/j.beha.2025.101641_bib26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1373\/clinchem.2015.242651","article-title":"Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration","volume":"62","author":"Bergen","year":"2016","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.beha.2025.101641_bib27","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.jproteome.7b00890","article-title":"Development of a targeted mass-spectrometry serum assay to quantify M-Protein in the presence of therapeutic monoclonal antibodies","volume":"17","author":"Zajec","year":"2018","journal-title":"J Proteome Res"},{"issue":"11","key":"10.1016\/j.beha.2025.101641_bib28","doi-asserted-by":"crossref","first-page":"E368","DOI":"10.1002\/ajh.25244","article-title":"MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms","volume":"93","author":"Kourelis","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.beha.2025.101641_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41408-019-0180-1","article-title":"A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis","volume":"9","author":"Sharpley","year":"2019","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.beha.2025.101641_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-020-0291-8","article-title":"Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis","volume":"10","author":"Dispenzieri","year":"2020","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.beha.2025.101641_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.beha.2025.101641_bib32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1365-2141.1997.72653.x","article-title":"Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage","volume":"97","author":"Rawstron","year":"1997","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.beha.2025.101641_bib33","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1158\/1078-0432.CCR-22-1594","article-title":"Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma","volume":"28","author":"Termini","year":"2022","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"7","key":"10.1016\/j.beha.2025.101641_bib34","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.22.01226","article-title":"More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma","volume":"41","author":"Jelinek","year":"2023","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"27","key":"10.1016\/j.beha.2025.101641_bib35","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garces","year":"2022","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2025.101641_bib36","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood.2023022080","article-title":"Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma","volume":"143","author":"D'Agostino","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2025.101641_bib37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/2159-8290.CD-22-0482","article-title":"MinimuMM-seq: genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple Myeloma pathology","volume":"13","author":"Dutta","year":"2023","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.beha.2025.101641_bib38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-021-00480-w","article-title":"Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies","volume":"11","author":"Rognvaldsson","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.beha.2025.101641_bib39","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","article-title":"Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study","volume":"9","author":"El-Khoury","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.beha.2025.101641_bib40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term Follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2025.101641_bib41","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2025.101641_bib42","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.beha.2025.101641_bib43","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2025.101641_bib44","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2025.101641_bib45","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma","volume":"27","author":"Bianchi","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2025.101641_bib46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2141.2009.07929.x","article-title":"Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells","volume":"148","author":"Perez-Persona","year":"2010","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2025.101641_bib47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.beha.2025.101641_bib48","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type","volume":"123","author":"Rosinol","year":"2003","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.beha.2025.101641_bib49","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"34","key":"10.1016\/j.beha.2025.101641_bib50","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2025.101641_bib51","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4065\/mcp.2009.0653","article-title":"Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma","volume":"85","author":"Madan","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.beha.2025.101641_bib52","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/s41375-022-01529-w","article-title":"Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio >\/=100","volume":"36","author":"Visram","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2025.101641_bib53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.beha.2025.101641_bib54","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.beha.2025.101641_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.65","article-title":"Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma","volume":"6","author":"Ravi","year":"2016","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.beha.2025.101641_bib56","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression","volume":"32","author":"Fernandez de Larrea","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2025.101641_bib57","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1182\/blood-2022-165371","article-title":"Evolving pattern improves the IMWG 2\/20\/20 classification for patients with smoldering multiple myeloma. ASH","author":"Rodr\u00edguez-Lobato","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2025.101641_bib58","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/bloodadvances.2018016998","article-title":"Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling","volume":"2","author":"Wu","year":"2018","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.beha.2025.101641_bib59","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41408-021-00569-2","article-title":"Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.beha.2025.101641_bib60","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study","volume":"10","author":"Cowan","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2025.101641_bib61","series-title":"Improved risk stratification of Smoldering Multiple Myeloma (SMM) using trajectory data in the pangea 2.0 model: a multicenter study in 1,431 participants. ASH","first-page":"1017","author":"Chabrun","year":"2024"},{"issue":"16","key":"10.1016\/j.beha.2025.101641_bib62","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.22.01916","article-title":"Definition and clinical significance of the monoclonal gammopathy of undetermined significance-like phenotype in patients with monoclonal gammopathies","volume":"41","author":"Burgos","year":"2023","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"21","key":"10.1016\/j.beha.2025.101641_bib63","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101641_bib64","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1038\/s41467-022-30694-w","article-title":"Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes","volume":"13","author":"Bustoros","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.beha.2025.101641_bib65","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-0210","article-title":"Genomic profiling to contextualize the results of intervention for smoldering multiple myeloma","author":"Kazandjian","year":"2024","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.beha.2025.101641_bib66","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1038\/s41467-022-33944-z","article-title":"Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis","volume":"13","author":"Boiarsky","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.beha.2025.101641_bib67","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41467-024-55308-5","article-title":"Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial","volume":"16","author":"Nadeem","year":"2025","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.beha.2025.101641_bib68","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41588-025-02196-0","article-title":"Genomic landscape of multiple myeloma and its precursor conditions","volume":"57","author":"Alberge","year":"2025","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.beha.2025.101641_bib69","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"issue":"2","key":"10.1016\/j.beha.2025.101641_bib70","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/bloodadvances.2021005198","article-title":"FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology","volume":"6","author":"Botta","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.beha.2025.101641_bib71","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ccell.2022.10.017","article-title":"Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma","volume":"40","author":"Sklavenitis-Pistofidis","year":"2022","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.beha.2025.101641_bib72","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.beha.2025.101641_bib73","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.beha.2025.101641_bib74","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","article-title":"Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study","volume":"174","author":"Mateos","year":"2022","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.beha.2025.101641_bib75","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","article-title":"Carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with high-risk smoldering myeloma: a phase 2 nonrandomized controlled trial","volume":"7","author":"Kazandjian","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beha.2025.101641_bib76","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/blood-2022-159606","article-title":"Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): post-hoc analysis of sustained undetectable Measurable Residual Disease (MRD). ASH","author":"Mateos","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101641_bib77","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.1182\/blood-2022-157302","article-title":"Isatuximab in combination with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma: updated safety Run-in results from the randomized phase 3 ithaca study. ASH","author":"Mateos","year":"2022","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2025.101641_bib78","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood.2020008787","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"137","author":"Facon","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101641_bib79","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.beha.2025.101641_bib80","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.beha.2025.101641_bib81","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2025.101641_bib82","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.beha.2025.101641_bib83","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1182\/bloodadvances.2023010162","article-title":"CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies","volume":"7","author":"Perez de Acha","year":"2023","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.beha.2025.101641_bib84","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"4","key":"10.1016\/j.beha.2025.101641_bib85","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101641_bib86","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2025.101641_bib87","series-title":"Phase II trial of daratumumab, Bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma. ASH","first-page":"3360","author":"Nadeem","year":"2024"},{"issue":"27","key":"10.1016\/j.beha.2025.101641_bib88","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1200\/JCO.23.02771","article-title":"Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance","volume":"42","author":"Mateos","year":"2024","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2025.101641_bib89","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.beha.2025.101641_bib90","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.beha.2025.101641_bib91","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.beha.2025.101641_bib92","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101641_bib93","first-page":"JCO2500760","article-title":"Long-term (>\/=5-Year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.beha.2025.101641_bib94","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.beha.2025.101641_bib95","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.beha.2025.101641_bib96","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2025.101641_bib97","first-page":"206","article-title":"Immuno-PRISM: a randomized phase II platform study of bispecific antibodies in high-risk smoldering myeloma","author":"Nadeem","year":"2023","journal-title":"ASH: Blood"},{"key":"10.1016\/j.beha.2025.101641_bib98","series-title":"Ash","first-page":"1027","article-title":"Early safety and efficacy of CAR-T cell therapy in precursor myeloma: results of the CAR-PRISM study using ciltacabtagene autoleucel in high-risk smoldering myeloma","author":"Nadeem","year":"2024"},{"issue":"19","key":"10.1016\/j.beha.2025.101641_bib99","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.beha.2025.101641_bib100","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.beha.2025.101641_bib101","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.beha.2025.101641_bib102","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2025.101641_bib103","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41591-025-03499-9","article-title":"Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody","volume":"31","author":"Braun","year":"2025","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.beha.2025.101641_bib104","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMoa2309728","article-title":"CAR+ T-Cell lymphoma after cilta-cel therapy for relapsed or refractory myeloma","volume":"392","author":"Harrison","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101641_bib105","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/blood-2023-179356","article-title":"Trial in progress: a phase 2 study of Linvoseltamab for the treatment of high-risk smoldering multiple myeloma (LINKER-SMM1). ASH","author":"Rodriguez Otero","year":"2023","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:54:09Z","timestamp":1757094849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692625000465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1521692625000465"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2025.101641","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precursor plasma cell disorders: Classification, risk stratification, and emerging role of early interception","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2025.101641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101641"}}